graft vs host disease

With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Fierce Pharma
Wed, 10/30/24 - 11:42 am
Incyte
Jakafi
patent cliff
Niktimvo
graft vs host disease
Monjuvi
follicular lymphoma
Zynyz
squamous cell anal carcinoma
Zephyrm rides IPO updraft toward Hong Kong listing, seeking cash for phase 3 cell therapy trials
Fierce Biotech
Wed, 10/2/24 - 10:40 am
Zephyrm Bioscience
Hong Kong
IPOs
cell therapy
graft vs host disease
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug
Clinical Trials Arena
Tue, 09/24/24 - 09:56 pm
ReAlta Life Sciences
RLS-0071
graft vs host disease
clinical trials
Incyte and Syndax's immunotherapy for transplant complications receives FDA approval
Biopharma Reporter
Tue, 08/20/24 - 11:49 am
Incyte
Syndax
immunotherapy
Niktimvo
graft vs host disease
FDA approves Incyte's treatment for chronic graft-versus-host disease
Reuters
Wed, 08/14/24 - 10:37 pm
Incyte
FDA
graft vs host disease
Niktimvo
MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement
Clinical Trials Arena
Mon, 04/15/24 - 11:20 am
MaaT Pharma
MaaT013
graft vs host disease
clinical trials
Ironwood spies new frontier for $1B GLP-2 analog in exploratory phase 2 rare disease trial
Fierce Biotech
Thu, 03/28/24 - 11:16 am
Ironwood Pharmaceuticals
apraglutide
VectaBio
graft vs host disease
Microbiome-based treatment shows potential in graft-versus-host disease
Biopharma Reporter
Tue, 12/19/23 - 10:16 am
MaaT Pharma
microbiome
graft vs host disease
MaaT013
Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting
BioSpace
Thu, 09/21/23 - 10:38 am
Mesoblast
remestemcel-L
FDA
graft vs host disease
FDA Blocks Mesoblast Cell Therapy Again, Asks for More Data
BioSpace
Sun, 08/6/23 - 09:34 pm
Mesoblast
remestemcel-L
FDA
graft vs host disease
cell therapy
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
After 20-month hold, FDA drops resistance to fecal pooling, clears MaaT to run pivotal trial
Fierce Biotech
Tue, 04/25/23 - 10:37 am
MaaT Pharma
FDA
clinical trials
fecal therapy
graft vs host disease
Takeda’s Vedolizumab Clears Phase III in aGvHD
BioSpace
Tue, 02/21/23 - 10:03 am
Takeda
vedolizumab
graft vs host disease
clinical trials
2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission
Fierce Biotech
Sun, 11/27/22 - 07:05 pm
Mesoblast
FDA
cell therapy
remestemcel-L
graft vs host disease
AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease
Fierce Pharma
Thu, 08/25/22 - 11:04 am
JNJ
AbbVie
Imbruvica
graft vs host disease
pediatric
FDA
FDA declines to free MaaT's microbiome drug from clinical hold after a year
Fierce Biotech
Wed, 08/10/22 - 11:31 pm
MaaT Pharma
FDA
microbiome
clinical trials
graft vs host disease
Sanofi's latest analysis of Rezurock can inform future research, company says
Fierce Pharma
Thu, 04/21/22 - 10:34 am
Sanofi
Kadmon
M&A
graft vs host disease
Rezurock
AbbVie files sNDA to FDA for chronic graft versus host disease therapy
Pharmaceutical Business Review
Tue, 03/1/22 - 10:24 am
AbbVie
Imbruvica
graft vs host disease
FDA
Bristol Myers drug wins first U.S. approval for Graft versus Host Disease prevention
Reuters
Wed, 12/15/21 - 11:54 pm
Bristol Myers Squibb
Orencia
FDA
graft vs host disease
Incyte and Syndax to jointly develop and commercialize axatilimab
Pharmaceutical Business Review
Tue, 09/28/21 - 12:01 pm
Incyte
Syndax Pharma
axatilimab
graft vs host disease

Pages